
    
      Twenty Russian centers were approved for participation in this study. Twelve centers were
      initiated. Patients were enrolled in 12 centers. The study consisted of 4 periods: Screening,
      Run-In Period, Treatment Period, and Follow-up. All eligible patients were randomized into
      one of four treatment groups in a ratio of 1:1:1:1.

      Treatment group of XC8 2 mg daily (30 patients) Treatment group of XC8 10 mg daily (30
      patients) Treatment group of XC8 100 mg daily (30 patients) Treatment group of Placebo (30
      patients) The study drug was manufactured by order Pharmenterprises LLS, Russia and Eurrus
      Biotech GmbH, Austria. During the treatment period (12 weeks) patients took the study drug or
      Placebo once a day in addition to stable low doses of Inhaled Corticosteroids (ICS) with or
      without long-acting beta2-agonists (LABA). The follow-up period lasted for 4 weeks.
    
  